Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 270-280

  Schultz, J D ^a   Sommer, J U ^a   Hoedt, S ^a   Erben, P ^a   Hofheinz, R D ^a   Faber, A ^a   Thorn, C ^a   Hormann K ^a   Sauter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

catenin; C kit; Head and neck squamous cell carcinoma; Human papillomavirus; Imatinib; Protein tyrosine kinase

Indexed keywords

BETA CATENIN; CARBOPLATIN; IMATINIB; PLATINUM COMPLEX; PROTEIN P16; STEM CELL FACTOR RECEPTOR;

ARTICLE; CARCINOMA CELL; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INCUBATION TIME; MOLECULAR THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VIRUS CELL TRANSFORMATION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRUS INFECTIONS; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; STEM CELL FACTOR; VIRAL CORE PROTEINS;

EID: 84855269201     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1499     Document Type: Article

References (82)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. J Clin Cancer 55: 74-108, 2002. (Pubitemid 40372904)
2. IARC (International Agency for Research on Cancer): Globocan. www.dep.iarc.fr, 2002.
3. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review 1975-2002. National Cancer Institute, Bethesda MD, http://seer.cancer.gov/csr/ 1975-2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005.
4. Romanitan M, Näsman A, Ramqvist T, et al.: Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 28: 2077-2080, 2008.
5. Chaturvedi AK, Engels EA, Anderson WF and Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008. (Pubitemid 351264356)
6. Gillison ML, D'Souza G, Westra W, et al.: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420, 2008. (Pubitemid 351480511)
7. Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103: 1843-1849, 2005. (Pubitemid 40563256)
8. Näsman A, Attner P, Hammarstedt L, et al.: Incidence of human papilloma virus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral induced carcinoma? Int J Cancer 125: 362-366, 2009.
9. Dilianis T, Näsman A, Attner P, et al.: Human papillomavirus in tonsillar cancer, an epidemic of viral carcinoma. 25th International Papillomavirus Conference and Clinical Workshop; Malmö, Sweden May 8-14, Abst O17.04, 2009.
10. Hansson BG, Rosenquist K, Antonsson A, et al.: Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case control study in southern Sweden. Acta Otolaryngol 125: 1337-1344, 2005. (Pubitemid 41722001)
11. Brandsma JL and Abramson AL: Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 115: 621-625, 1989. (Pubitemid 19130305)
12. Pyeon D, Lambert PF and Ahlquist P: Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci USA 102: 9311-9316, 2005. (Pubitemid 40923560)
13. Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517, 2002. (Pubitemid 34226138)
14. Califano J, van der Reit P, Westra W, et al.: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996. (Pubitemid 26170679)
15. Goodwin EC and DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl Acad Sci USA 97: 12513-12518, 2000.
16. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR and Schiller JT: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8: 3905-3910, 1989. (Pubitemid 20016074)
17. Sidransky D: Molecular genetics of head and neck cancer. Curr Opin Oncol 7: 229-233, 1995.
18. McDougall JK: Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol 186: 101-119, 1994.
19. Narisawa-Saito M and Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 98: 1505-1511, 2007. (Pubitemid 47308443)
20. Tang X, Zhang Q, Nishitani J, et al.: Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13: 2568-2576, 2007. (Pubitemid 46795128)
21. Hunter T: Oncoprotein networks. Cell 88: 333-346, 1997.
22. Vogel A, Rodriguez C, Warnken W and Izpisua Belmonte JC: Dorsal cell fate specified by chick Lmx1 during vertebrate limb development. Nature 378: 716-720, 1995.
23. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
24. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003. (Pubitemid 36713796)
25. Clevers H: Wnt/β-catenin signaling in development and disease. Cell 127: 469-480, 2006.
26. Kikuchi A: Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94: 225-229, 2003.
27. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003. (Pubitemid 36627817)
28. Sauter A, Soulsby H, Hormann K and Naim R: Sulindac sulfone induces a decrease of β-catenin in HNSCC. Anticancer Res 30: 339-343, 2010.
29. Aberle H, Schwartz H and Kemler R: Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61: 514-523, 1996. (Pubitemid 26240128)
30. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005. (Pubitemid 41267170)
31. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2: 442-454, 2002.
32. Leethanakul C, Patel V, Gillespie J, et al.: Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene 19: 3220-3224, 2000. (Pubitemid 30455935)
33. Rhee CS, Sen M, Lu D, et al.: Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21: 6598-6605, 2002. (Pubitemid 35177038)
34. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993. (Pubitemid 24036021)
35. Yang F, Zeng Q, Yu G, Li S and Wang CY: Wnt/β-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 18: 679-687, 2006. (Pubitemid 43113298)
36. Nelson WJ and Nusse R: Convergence of Wnt, β-catenin, and cadherin pathways. Science 303: 1483-1487, 2004. (Pubitemid 38314410)
37. Hart MJ, de los Santos R, Albert IN, Rubinfeld B and Polakis P: Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK-3β. Curr Biol 8: 573-581, 1998. (Pubitemid 28222891)
38. Sakanaka C, Weiss JB and Williams LT: Bridging of β-catenin and glycogen synthase kinase-3β by axin and inhibition of β-catenin- mediated transcription. Proc Natl Acad Sci USA 95: 3020-3023, 1998. (Pubitemid 28135847)
39. Hajra KM and Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34: 255-268, 2002. (Pubitemid 34553304)
40. Cantley LC, Auger KR, Carpenter C, et al.: Oncogenes and signal transduction. Cell 64: 281-302, 1991. (Pubitemid 121001255)
41. Blume-Jensen P and Hunter T: Oncogenic kinase signaling. Nature 411: 355-365, 2001.
42. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, et al.: Identification of a ligand for the c-kit proto-oncogene. Cell 63: 167-174, 1990.
43. Trieselmann NZ, Soboloff J and Berger SA: Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 60: 759-766, 2003. (Pubitemid 36570766)
44. Caruana G, Cambareri AC and Ashman LK: Isoforms of c-KIT differ in activation of signaling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18: 5573-5581, 1999. (Pubitemid 29481504)
45. Broudy VC: Stem cell factor and hematopoiesis. Blood 90: 1345-1364, 1997.
46. Welker P, Schadendorf D, Artuc M, Grabbe J and Henz BM: Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer 82: 1453-1458, 2000. (Pubitemid 30175913)
47. Zheng R, Klang K, Gorin NC and Small D: Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk Res 28: 121-126, 2004. (Pubitemid 37487991)
48. Hines SJ, Organ C, Kornstein MJ and Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 6: 769-779, 1995.
49. Ongkeko WM, Altuna X, Weisman RA and Wang-Rodriguez J: Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124: 71-76, 2005. (Pubitemid 40944376)
50. Bruce IA, Slevin NJ, Homer JJ, McGrown AT and Ward TH: Synergistic effects of imatinib in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 16: 719-726, 2005. (Pubitemid 41104920)
51. Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine-kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000. (Pubitemid 30036380)
52. O'Dwyer ME, Mauro MJ and Druker BJ: STI571 as a targeted therapy for CML. Cancer Invest 21: 429-438, 2003. (Pubitemid 37055675)
53. Roskoski R Jr: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309: 709-717, 2003.
54. Shore SK, Bogart SL and Reddy EP: Activation of murine c-Abl protooncogene: effect of a point mutation on oncogenic activation. Proc Natl Acad Sci USA 87: 6502-6506, 1990.
55. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002. (Pubitemid 34879334)
56. Croom KF and Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumors. Drugs 63: 513-522, 2003. (Pubitemid 36337730)
57. Vlahovic G, Ponce AM, Rabbani Z, et al.: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97: 735-740, 2007. (Pubitemid 47396288)
58. Wang-Rodriguez J, Lopez JP and Altuna X: STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 116: 1409-1416, 2006. (Pubitemid 44181456)
59. Schultz JD, Rotunno S, Sauter A, et al.: Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/β expression in squamous cell carcinoma of the head and neck in vitro. Int J Oncol 38: 1001-1012, 2011.
60. Adler PN and Lee H: Frizzled signaling and cell-cell interactions in planar polarity. Curr Opin Cell Biol 13: 635-640, 2001. (Pubitemid 32817024)
61. Saldanha J, Singh J and Mahadevan D: Identification of a Frizzled-like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases. Protein Sci 7: 1632, 1998.
62. Gillison ML: Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31: 744-754, 2004.
63. D'Souza G, Kreimer AR, Viscidi R, et al.: Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med 356: 1944-1956, 2007. (Pubitemid 46740304)
64. Mork J, Lie AK, Glattre E, et al.: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New Engl J Med 344: 1125-1131, 2001. (Pubitemid 32285233)
65. Lindquist D, Romanitan M, Hammarstedt L, et al.: Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1: 350-355, 2007. (Pubitemid 350186274)
66. Lindel K, Beer KT, Laissue J, Greiner RH and Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805-813, 2001. (Pubitemid 32783066)
67. Bristow RG, Benchimol S and Hill RP: The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40: 197-223, 1996. (Pubitemid 27314227)
68. Dahm-Daphi J: p53: biology and role for cellular radiosensitivity. Strahlenther Onkol 176: 278-285, 2000.
69. Nelson AR, Fingleton BM, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
70. Hellner K and Münger K: Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol 29: 1785-1794, 2011.
71. Hellner K, Mar J, Fang F, et al.: HPV16 E7 oncogene expression in normal human epithelial cells causes molecular changes indicative of an epithelial to mesenchymal transition. Virology 391: 57-63, 2009.
72. Hayward SD, Liu, J and Fujimuro M: Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE 2006: re4, 2006.
73. Rampias T, Boutati E, Pectasides E, et al.: Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 8: 433-443, 2010.
74. Al Moustafa AE, Foulkes WD, Benlimame N, et al.: E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23: 350-358, 2004. (Pubitemid 38174988)
75. Uren A, Fallen S, Yuan H, et al.: Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res 65: 6199-6206, 2005. (Pubitemid 40994405)
76. Lichtig H, Gilboa DA, Jackman A, Gonen P, Levav-Cohen Y, Haupt Y and Sherman L: HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 396: 47-58, 2010.
77. Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, et al.: Nuclear β-catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 54: 42-47, 2001. (Pubitemid 32048294)
78. Lopez-Gonzalez JS, Cristerna-Sanchez L, Vazquez-Manriquez ME, Jimenez-Orci G, Aguilar-Cazares D: Localization and level of expression of beta-catenin in human laryngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 130: 89-93, 2004. (Pubitemid 38113921)
79. Hirvikoski P, Kumpulainen EJ, Virtaniemi JA, Helin HJ, Rantala I, Johansson RT, Juhola M and Kosma VM: Cytoplasmic accumulation of alpha-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma. Int J Cancer 79: 546-550, 1998. (Pubitemid 28445281)
80. Welker P, Grabbe J, Gibbs B Zuberbier T and Henz BM: Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor. Scand J Immunol 49: 495-500, 1999. (Pubitemid 29243121)
81. Doneda L, Klinger FG, Larizza L and de Felici M: KL/KIT co-expression in mouse fetal oocytes. Int J Dev Biol 46: 1015-1021, 2002. (Pubitemid 36119741)
82. Caruana G, Cambareri AC, Gonda TJ and Ashman LK: Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. Oncogene 16: 179-190, 1998. (Pubitemid 28045103)